Osteoarthristis (OA)

 
 

What is Arthritis?

Arthritis is a condition in which one or more of your joints are inflamed. This can result in stiffness, soreness and in many cases swelling. Inflammatory and non-inflammatory arthritis are the two most common forms of the condition. Inflammatory arthritis is usually referred to as rheumatoid arthritis (RA) and non-inflammatory arthritis is known as osteoarthritis (OA).

Causes of arthritis

i) Osteoarthritis (OA)

Even though it is called non-inflammatory arthritis, OA can still result in some inflammation of the joints. This inflammation results from wear and tear. In particular, OA re-sults from the breakdown of cartilage. Cartilage is the slick tissue that covers and cushions the ends of the bones in a joint.

ii) Rheumatoid Arthritis (RA)

RA is an autoimmune disease. This means the body’s immune system attacks healthy tissue. The cause of RA still remains a mystery. However, because women are more likely to develop RA than men are, researchers believe that it may involve genetic or hormonal factors.


What is Medi-Kine?

i) Medi-Kine is cytokine. The term “cytokine” is derived from a combination of two Greek words –“cyto” meaning cell and “kinos” meaning movement.

ii) Cytokines are cell signalling molecules that aid cell to cell communication in immune response and stimulate the movement of cell towards sites of inflammation, infection and trauma.

iii) Cytokines is “immunomodulating agents” that modulate or alter the immune system response. Cytokines are important regulators of both the innate and adaptive immune response.

The potential of Medi-Kine

  • Notable advances have been made by specific targeting of Medi-Kine for the treatment of various diseases. In the treatment of inflammatory disorders, such as rheumatoid arthritis and Crohn's disease, anti-tumor necrosis factor therapies have proved to be very successful. Cancer therapy was redefined through the use of drugs that prevent growth factors, such as fibroblast growth factor (FGF) and epidermal growth factor (EGF), from influencing the tumor cells.
  • The clinical use of Medi-Kine has also been investigated in many other disease areas such as chronic renal failure, bone marrow failure, ophthalmology, and acquired immunodeficiency syndrome.
  • Antibody-Medi-Kine fusions have been used for Medi-Kine therapies in order to localize Medi-Kine activity to the preferred area, and as a result, the systemic dose-limiting side effects are reduced. When tumors are the target, side effects present issues even though the treatment potential showed improvement in many areas.